Key PointsQuestionIs the use of a placebo run-in (PRI) period associated with different outcomes among randomized clinical trials (RCTs) of antidepressants? FindingsIn this systematic review and meta-analysis of 347 RCTs of antidepressants comprising 89 183 participants, the use of PRI periods was associated with a lower placebo and drug response but was not associated with the drug-placebo difference. MeaningThis study suggests that the use of PRI periods is common in RCTs of antidepressants, despite offering no apparent benefits to RCT outcomes; given the risks and costs of PRI periods, their practice should be ceased.
JAMA Psychiatry – American Medical Association
Published: Jan 10, 2022